Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications

References

• Abdel-Rahman SZ, Salama SA, Au WW, Hamada FA. (2000). Role of polymorphic CYP2E1 and CYP2D6 genes in NNK-induced chromosome aberrations in cultured human lymphocytes. Pharmacogenetics 10:239–249
   PubMedGoogle Scholar
• Agundez JA, Martinez C, Benitez J. (1995). Metabolism of aminopyrine and derivatives in man: In vivo study of monomorphic and polymorphic metabolic pathways. Xenobiotica 25:417–427
   PubMed Web of Science ®Google Scholar
• Ahlstrom MM, Ridderstrom M, Zamora I. (2007). CYP2C9 structure-metabolism relationships: Substrates, inhibitors, and metabolites. J Med Chem 50:5382–5391
   PubMed Web of Science ®Google Scholar
• Andersson T, Miners JO, Veronese ME, Birkett DJ. (1994). Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 37:597–604
   PubMed Web of Science ®Google Scholar
• Antunes AMM, Godinho ALA, Martins IsL, et al. (2010). Protein adducts as prospective biomarkers of nevirapine toxicity. Chem Res Toxicol 23:1714–1725
   PubMed Web of Science ®Google Scholar
• Arlt VM, Stiborova M, Hewer A, et al. (2003). Human enzymes involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone: Evidence for reductive activation by human NADPH:cytochrome P450 reductase. Cancer Res 63:2752–2761
   PubMed Web of Science ®Google Scholar
• Armstrong M, Daly AK, Cholerton S, et al. (1992). Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 339:1017–1018
   PubMed Web of Science ®Google Scholar
• Bach MV, Coutts RT, Baker GB. (1999). Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica 29:719–732
   PubMed Web of Science ®Google Scholar
• Bach MV, Coutts RT, Baker GB. (2000). Metabolism of N,N-dialkylated amphetamines, including deprenyl, by CYP2D6 expressed in a human cell line. Xenobiotica 30:297–306
   PubMed Web of Science ®Google Scholar
• Bachus R, Bickel U, Thomsen T, et al. (1999). The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 9:661–668
   PubMedGoogle Scholar
• Bae SH, Lee JK, Cho DY, Bae SK. (2014). Simultaneous determination of metoprolol and its metabolites, alpha-hydroxymetoprolol and O-desmethylmetoprolol, in human plasma by liquid chromatography with tandem mass spectrometry: Application to the pharmacokinetics of metoprolol associated with CYP2D6 genotypes. J Sep Sci 37:1256–1264
   PubMed Web of Science ®Google Scholar
• Baer BR, Rettie AE, Henne KR. (2005). Bioactivation of 4-ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediate. Chem Res Toxicol 18:855–864
   PubMed Web of Science ®Google Scholar
• Bajpai P, Sangar MC, Singh S, et al. (2013). Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: Implications in Parkinson disease. J Biol Chem 288:4436–4451
   PubMed Web of Science ®Google Scholar
• Baker MT, Olson MJ, Wang Y, et al. (1995). Isoflurane-chlorodifluoroethene interaction in human liver microsomes. Role of cytochrome P4502B6 in potentiation of haloethene metabolism. Drug Metab Dispos 23:60–64
   PubMed Web of Science ®Google Scholar
• Beach SR, Celano CM, Noseworthy PA, et al. (2013). QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 54:1–13
   PubMed Web of Science ®Google Scholar
• Beckett AH, Chidomere EC. (1977). The identification and analysis of mexiletine and its metabolic products in man. J Pharm Pharmacol 29:281–285
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Alm C, Carreras Cd, et al. (1989). Debrisoquine hydroxylation polymorphism and personality. Lancet 333:555–556
   Google Scholar
• Beverage JN, Sissung TM, Sion AM, et al. (2007). CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 96:2224–2231
   PubMed Web of Science ®Google Scholar
• Bichara N, Ching MS, Blake CL, et al. (1996). Propranolol hydroxylation and N-desisopropylation by cytochrome P4502D6: Studies using the yeast-expressed enzyme and NADPH/O2 and cumene hydroperoxide-supported reactions. Drug Metab Dispos 24:112–118
   PubMed Web of Science ®Google Scholar
• Bloomer JC, Woods FR, Haddock RE, et al. (1992). The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 33:521–523
   PubMed Web of Science ®Google Scholar
• Bogaards JJ, Bertrand M, Jackson P, et al. (2000). Determining the best animal model for human cytochrome P450 activities: A comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131–1152
   PubMed Web of Science ®Google Scholar
• Bolaji OO, Coutts RT, Baker GB. (1993). Metabolism of trimipramine in vitro by human CYP2D6 isozyme. Res Commun Chem Pathol Pharmacol 82:111–120
   PubMedGoogle Scholar
• Bon MA, Jansen Steur EN, de Vos RA, Vermes I. (1999). Neurogenetic correlates of Parkinson's disease: Apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism. Neurosci Lett 266:149–151
   PubMed Web of Science ®Google Scholar
• Borges S, Desta Z, Li L, et al. (2006). Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61–74
   PubMed Web of Science ®Google Scholar
• Boyer D, Bauman JN, Walker DP, et al. (2009). Utility of MetaSite in improving metabolic stability of the neutral indomethacin amide derivative and selective cyclooxygenase-2 inhibitor 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-phenethyl-acetamide. Drug Metab Dispos 37:999–1008
   PubMed Web of Science ®Google Scholar
• Brachtendorf L, Jetter A, Beckurts KT, et al. (2002). Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol 90:144–149
   PubMedGoogle Scholar
• Brix-Christensen V, Tonnesen E, Sanchez RG, et al. (1997). Endogenous morphine levels increase following cardiac surgery as part of the antiinflammatory response? Int J Cardiol 62:191–197
   PubMed Web of Science ®Google Scholar
• Brockmoller J, Kirchheiner J, Schmider J, et al. (2002). The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 72:438–452
   PubMed Web of Science ®Google Scholar
• Broly F, Libersa C, Lhermitte M, Dupuis B. (1990). Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem Pharmacol 39:1045–1053
   PubMed Web of Science ®Google Scholar
• Broly F, Vandamme N, Libersa C, Lhermitte M. (1991). The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation. Br J Clin Pharmacol 32:459–466
   PubMed Web of Science ®Google Scholar
• Bromek E, Haduch A, Daniel WA. (2010). The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: An in vitro study. Eur J Pharmacol 626:171–178
   PubMed Web of Science ®Google Scholar
• Brosen K, Zeugin T, Meyer UA. (1991). Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 49:609–617
   PubMed Web of Science ®Google Scholar
• Bu W, Akama T, Chanda S, et al. (2012). Early rapid identification of in vivo rat metabolites of AN6414, a novel boron-containing PDE4 inhibitor by QTRAP LC/MS/MS to support drug discovery. J Pharm Biomed Anal 70:344–353
   PubMed Web of Science ®Google Scholar
• Butler AM, Murray M. (1997). Biotransformation of parathion in human liver: Participation of CYP3A4 and its inactivation during microsomal parathion oxidation. J Pharmacol Exp Ther 280:966–973
   PubMed Web of Science ®Google Scholar
• Cadet P, Mantione KJ, Stefano GB. (2003). Molecular identification and functional expression of μ3, a novel alternatively spliced variant of the human μ opiate receptor gene. J Immunol 170:5118–5123
   PubMed Web of Science ®Google Scholar
• Caldwell J, Dring LG, Williams RT. (1972). Metabolism of (14 C)methamphetamine in man, the guinea pig and the rat. Biochem J 129:11–22
   PubMed Web of Science ®Google Scholar
• Cao JL, Varnell AL, Cooper DC. (2011). Gulf War Syndrome: A role for organophosphate induced plasticity of locus coeruleus neurons. Nature Precedings. Available from: http://dx.doi.org/10.1038/npre.2011.6057.2 [last accessed May 2015]
   Google Scholar
• Carrillo JA, Dahl ML, Svensson JO, et al. (1996). Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 60:183–190
   PubMed Web of Science ®Google Scholar
• CDC. (1999). Suicide: Risk and protective factors. risk factors for suicide. Available at: http://www.cdc.gov/violenceprevention/suicide/riskprotectivefactors.html [last accessed May 2015]
   Google Scholar
• Chen S, Chou W-H, Blouin RA, et al. (1996). The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60:522–534
   PubMed Web of Science ®Google Scholar
• Chen W, Koenigs LL, Thompson SJ, et al. (1998). Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem Res Toxicol 11:295–301
   PubMed Web of Science ®Google Scholar
• Cheng J, Zhen Y, Miksys S, et al. (2013). Potential role of CYP2D6 in the central nervous system. Xenobiotica 43:973–984
   PubMed Web of Science ®Google Scholar
• Chow T, Hiroi T, Imaoka S, et al. (1999). Isoform-selective metabolism of mianserin by cytochrome P-450 2D. Drug Metab Dispos 27:1200–1204
   PubMed Web of Science ®Google Scholar
• Chuang LF, Killam KF Jr, Chuang RY. (1997). Induction and activation of mitogen-activated protein kinases of human lymphocytes as one of the signaling pathways of the immunomodulatory effects of morphine sulfate. J Biol Chem 272:26815–26817
   PubMed Web of Science ®Google Scholar
• Chung WG, Park CS, Roh HK, et al. (2000). Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol 84:213–220
   PubMedGoogle Scholar
• Churchill FC, Mount DL, Patchen LC, Bjorkman A. (1986). Isolation, characterization and standardization of a major metabolite of amodiaquine by chromatographic and spectroscopic methods. J Chromatogr 377:307–318
   PubMed Web of Science ®Google Scholar
• Cochran WG. (1950). The comparison of percentages in matched samples. Biometrika 37:256–266
   PubMed Web of Science ®Google Scholar
• Cooper SJ, Kelly CB, King DJ. (1992). 5-Hydroxyindoleacetic acid in cerebrospinal fluid and prediction of suicidal behaviour in schizophrenia. Lancet 340:940–941
   PubMed Web of Science ®Google Scholar
• Coutts RT, Bolaji OO, Su P, Baker GB. (1994). Metabolism of methoxyphenamine in vitro by a CYP2D6 microsomal preparation. Drug Metab Dispos 22:756–760
   PubMed Web of Science ®Google Scholar
• Crewe HK, Notley LM, Wunsch RM, et al. (2002). Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: Formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869–874
   PubMed Web of Science ®Google Scholar
• Cruciani G, Carosati E, De Boeck B, et al. (2005). MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem 48:6970–6979
   PubMed Web of Science ®Google Scholar
• Dahl ML, Ekqvist B, Widen J, Bertilsson L. (1991a). Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 84:99–102
   PubMed Web of Science ®Google Scholar
• Dahl ML, Nordin C, Bertilsson L. (1991b). Enantioselective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline. Ther Drug Monit 13:189–194
   PubMed Web of Science ®Google Scholar
• Dain JG, Fu E, Gorski J, et al. (1993). Biotransformation of fluvastatin sodium in humans. Drug Metab Dispos 21:567–572
   PubMed Web of Science ®Google Scholar
• Dambach DM, Andrews BA, Moulin F. (2005). New technologies and screening strategies for hepatotoxicity: Use of in vitro models. Toxicol Pathol 33:17–26
   PubMed Web of Science ®Google Scholar
• Davies BJ, Coller JK, Somogyi AA, et al. (2007). CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos 35:128–138
   PubMed Web of Science ®Google Scholar
• Davis JA, Rock DA, Wienkers LC, Pearson JT. (2012). In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates. Drug Metab Dispos 40:1927–1934
   PubMed Web of Science ®Google Scholar
• Dayer P, Gasser R, Gut J, et al. (1984). Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)-increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizers. Biochem Biophys Res Commun 125:374–380
   PubMed Web of Science ®Google Scholar
• Dehal SS, Kupfer D. (1994). Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Dual pathways involving novel ortho ring-hydroxylation by CYP2B. Drug Metab Dispos 22:937–946
   PubMed Web of Science ®Google Scholar
• Dehal SS, Kupfer D. (1997). CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57:3402–3406
   PubMed Web of Science ®Google Scholar
• Delbressine LP, Moonen ME, Kaspersen FM, et al. (1998). Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Investig 15:45–55
   PubMed Web of Science ®Google Scholar
• Deng P, Zhong D, Nan F, et al. (2010). Evidence for the bioactivation of 4-nonylphenol to quinone methide and ortho-benzoquinone metabolites in human liver microsomes. Chem Res Toxicol 23:1617–1628
   PubMed Web of Science ®Google Scholar
• Desager JP. (1994). Clinical pharmacokinetics of ticlopidine. Clin Pharmacokinet 26:347–355
   PubMed Web of Science ®Google Scholar
• Desta Z, Wu GM, Morocho AM, Flockhart DA. (2002). The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 30:336–343
   PubMed Web of Science ®Google Scholar
• DeVoe K Jr, Rigsby WC, DeVoe SJ, et al. (1969). Effect of spartein sulfate on uterine contractility. Am J Obstet Gynecol 105:304–308
   PubMed Web of Science ®Google Scholar
• Dick RA, Kanne DB, Casida JE. (2005). Identification of aldehyde oxidase as the neonicotinoid nitroreductase. Chem Res Toxicol 18:317–323
   PubMed Web of Science ®Google Scholar
• Djebaili M, Guo Q, Pettus EH, et al. (2005). The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma 22:106–118
   PubMed Web of Science ®Google Scholar
• Dong H, Haining RL, Thummel KE, et al. (2000). Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos 28:1397–1400
   PubMed Web of Science ®Google Scholar
• Dragovic S, Gunness P, Ingelman-Sundberg M, et al. (2013). Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab Dispos 41:651–658
   PubMed Web of Science ®Google Scholar
• Duff HJ, Dawson AK, Roden DM, et al. (1983). Electrophysiologic actions of O-demethyl encainide: An active metabolite. Circulation 68:385–391
   PubMed Web of Science ®Google Scholar
• Eagling VA, Wiltshire H, Whitcombe IW, Back DJ. (2002). CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 32:1–17
   PubMed Web of Science ®Google Scholar
• Eap CB, Bender S, Gastpar M, et al. (2000). Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. Ther Drug Monit 22:209–214
   PubMed Web of Science ®Google Scholar
• Eaton DL. (2000). Biotransformation enzyme polymorphism and pesticide susceptibility. Neurotoxicology 21:101–111
   PubMed Web of Science ®Google Scholar
• Ebner T, Eichelbaum M. (1993). The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism. Br J Clin Pharmacol 35:426–430
   PubMed Web of Science ®Google Scholar
• Ebner T, Meese CO, Eichelbaum M. (1995). Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans. Mol Pharmacol 48:1078–1086
   PubMed Web of Science ®Google Scholar
• Eiermann B, Edlund PO, Tjernberg A, et al. (1998). 1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans. Drug Metab Dispos 26:1096–1101
   PubMed Web of Science ®Google Scholar
• EMA. (2011). Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products. Committee for Medicinal Products for Human Use (CHMP). EMA/CHMP/37646/2009
   Google Scholar
• Emanuele E, Colombo R, Martinelli V, et al. (2010). Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia. Neuro Endocrinol Lett 31:117–121
   PubMed Web of Science ®Google Scholar
• Fabre G, Julian B, Saint-Aubert B, et al. (1993). Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 21:978–985
   PubMed Web of Science ®Google Scholar
• Fang J, Coutts RT, McKenna KF, Baker GB. (1998). Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol 358:592–599
   PubMed Web of Science ®Google Scholar
• Feifel N, Kucher K, Fuchs L, et al. (1993). Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor. Eur J Clin Pharmacol 45:265–269
   PubMed Web of Science ®Google Scholar
• Fischer V, Baldeck JP, Tse FL. (1992). Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans. Drug Metab Dispos 20:603–607
   PubMed Web of Science ®Google Scholar
• Fischer V, Johanson L, Heitz F, et al. (1999). The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 27:410–416
   PubMed Web of Science ®Google Scholar
• Fischer V, Vickers AE, Heitz F, et al. (1994). The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 22:269–274
   PubMed Web of Science ®Google Scholar
• Fischer V, Vogels B, Maurer G, Tynes RE. (1992). The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 260:1355–1360
   PubMed Web of Science ®Google Scholar
• Fitzsimmons ME, Collins JM. (1997). Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: Potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256–266
   PubMed Web of Science ®Google Scholar
• Fjordside L, Jeppesen U, Eap CB, et al. (1999). The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics 9:55–60
   PubMedGoogle Scholar
• Flanagan JU, Marechal JD, Ward R, et al. (2004). Phe120 contributes to the regiospecificity of cytochrome P450 2D6: Mutation leads to the formation of a novel dextromethorphan metabolite. Biochem J 380:353–360
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Ryan KK, Jansat JM, et al. (2001). Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol 51:437–441
   PubMed Web of Science ®Google Scholar
• Ford KA. (2013). Role of electrostatic potential in the in silico prediction of molecular bioactivation and mutagenesis. Mol Pharm 10:1171–1182
   PubMed Web of Science ®Google Scholar
• Fukuto JM, Kumagai Y, Cho AK. (1991). Determination of the mechanism of demethylenation of (methylenedioxy)phenyl compounds by cytochrome P450 using deuterium isotope effects. J Med Chem 34:2871–2876
   PubMed Web of Science ®Google Scholar
• Funae Y, Kishimoto W, Cho T, et al. (2003). CYP2D in the brain. Drug Metab Pharmacokinet 18:337–349
   PubMedGoogle Scholar
• Funck-Brentano C, Thomas G, Jacqz-Aigrain E, et al. (1992). Polymorphism of dextromethorphan metabolism: Relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther 263:780–786
   PubMed Web of Science ®Google Scholar
• Gantenbein M, Attolini L, Bruguerolle B, et al. (2000). Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos 28:383–385
   PubMed Web of Science ®Google Scholar
• Geertsen S, Foster BC, Wilson DL, et al. (1995). Metabolism of methoxyphenamine and 2-methoxyamphetamine in P4502D6-transfected cells and cell preparations. Xenobiotica 25:895–906
   PubMed Web of Science ®Google Scholar
• Gilham DE, Cairns W, Paine MJ, et al. (1997). Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 27:111–125
   PubMed Web of Science ®Google Scholar
• Glassman AH, Bigger JT Jr. (2001). Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158:1774–1782
   PubMed Web of Science ®Google Scholar
• Goetz MP, Knox SK, Suman VJ, et al. (2007). The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113–121
   PubMed Web of Science ®Google Scholar
• Goldenberg H, Fishman V, Heaton A, Burnett R. (1964). A detailed evaluation of promazine metabolism. Proc Soc Exp Biol Med 115:1044–1051
   PubMed Web of Science ®Google Scholar
• Gonzalez I, Penas-Lledo EM, Perez B, et al. (2008). Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 9:833–840
   PubMed Web of Science ®Google Scholar
• Grace JM, Kinter MT, Macdonald TL. (1994). Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,alpha-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem Res Toxicol 7:286–290
   PubMed Web of Science ®Google Scholar
• Gramec D, Peterlin Mašič L, Sollner Dolenc M. (2014). Bioactivation potential of thiophene-containing drugs. Chem Res Toxicol 27:1344–1358
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Von Moltke LL, Giancarlo GM, Garteiz DA. (2003). Human cytochromes mediating gepirone biotransformation at low substrate concentrations. Biopharm Drug Dispos 24:87–94
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. (1999). Human cytochromes mediating sertraline biotransformation: Seeking attribution. J Clin Psychopharmacol 19:489–493
   PubMed Web of Science ®Google Scholar
• Gross AS, Mikus G, Fischer C, et al. (1989). Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. Br J Clin Pharmacol 28:555–566
   PubMed Web of Science ®Google Scholar
• Gross AS, Phillips AC, Rieutord A, Shenfield GM. (1996). The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. Br J Clin Pharmacol 41:311–317
   PubMed Web of Science ®Google Scholar
• Gut J, Gasser R, Dayer P, et al. (1984). Debrisoquine-type polymorphism of drug oxidation: Purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation. FEBS Lett 173:287–290
   PubMed Web of Science ®Google Scholar
• Halliday RC, Jones BC, Smith DA, et al. (1995). An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: Studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 40:369–378
   PubMed Web of Science ®Google Scholar
• Haritos VS, Ching MS, Ghabrial H, et al. (1998). Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: Role of CYP2D6 and 1A2. Pharmacogenetics 8:423–432
   PubMedGoogle Scholar
• Heim MH, Meyer UA. (1992). Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 14:49–58
   PubMed Web of Science ®Google Scholar
• Hermansson J, Glaumann H, Karlen B, von Bahr C. (1980). Metabolism of lidocaine in human liver in vitro. Acta Pharmacol Toxicol (Copenh) 47:49–52
   PubMedGoogle Scholar
• Hilleret H, Voirol P, Bovier P, et al. (2002). Very long half-life of paroxetine following intoxication in an extensive cytochrome P4502D6 metabolizer. Ther Drug Monit 24:567–569
   PubMed Web of Science ®Google Scholar
• Hiroi T, Kishimoto W, Chow T, et al. (2001). Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 142:3901–3908
   PubMed Web of Science ®Google Scholar
• Hochman JH, Chiba M, Nishime J, et al. (2000). Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther 292:310–318
   PubMed Web of Science ®Google Scholar
• Hodgson E. (2001). In vitro human phase I metabolism of xenobiotics I: Pesticides and related chemicals used in agriculture and public health, September 2001. J Biochem Mol Toxicol 15:296–299
   PubMed Web of Science ®Google Scholar
• Hollander M, Wolfe DA. (1973). Nonparametric statistical methods. New York: Wiley
   Google Scholar
• Horikiri Y, Suzuki T, Mizobe M. (1998a). Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci 87:289–294
   PubMed Web of Science ®Google Scholar
• Horikiri Y, Suzuki T, Mizobe M. (1998b). Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci 63:1097–1108
   PubMed Web of Science ®Google Scholar
• Hornberger KR, Chen X, Crew AP, et al. (2013). Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: Optimization of kinase selectivity and pharmacokinetics. Bioorg Med Chem Lett 23:4511–4516
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. (1996). VMD: Visual molecular dynamics. J Mol Graph 14:33–38, 27–28
   PubMed Web of Science ®Google Scholar
• Hutchinson MR, Menelaou A, Foster DJ, et al. (2004). CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 57:287–297
   PubMed Web of Science ®Google Scholar
• Idle JR, Mahgoub A, Lancaster R, Smith RL. (1978). Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci 22:979–983
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6–13
   PubMed Web of Science ®Google Scholar
• Jajoo HK, Mayol RF, LaBudde JA, Blair IA. (1990). Structural characterization of urinary metabolites of the antiarrhythmic drug encainide in human subjects. Drug Metab Dispos 18:28–35
   PubMed Web of Science ®Google Scholar
• Jensen KG, Dalgaard L. (1999). In vitro metabolism of the M1-muscarinic agonist 5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine by human hepatic cytochromes P-450 determined at pH 7.4 and 8.5. Drug Metab Dispos 27:125–132
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Henne KR, Lame ME, et al. (2005). Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact 155:10–20
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Obach RS, Maurer TS. (2007). Mechanism-based inactivation of cytochrome P450 enzymes: Chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 8:407–447
   PubMed Web of Science ®Google Scholar
• Kang UG, Kwon JS, Ahn YM, et al. (2000). Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry 61:441–446
   PubMed Web of Science ®Google Scholar
• Kanmacher I, Millet P, Moachon G. (2000a). Buflomedil elimination: Relationship with CYP2D6 activity. Drug Metab Rev 32:67
   Google Scholar
• Kanmacher I, Oreal N, Andre N, et al. (2000b). Buflomedil metabolism in human liver microsomes. Drug Metab Rev 32:68
   Google Scholar
• Karbwang J, Na Bangchang K. (1994). Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet 27:104–119
   PubMed Web of Science ®Google Scholar
• Kariya S, Isozaki S, Uchino K, et al. (1996). Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull 19:1511–1514
   PubMed Web of Science ®Google Scholar
• Kassahun K, Mattiuz E, Nyhart E Jr, et al. (1997). Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 25:81–93
   PubMed Web of Science ®Google Scholar
• Kato D, Kawanishi C, Kishida I, et al. (2005). CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: Preliminary report. Psychiatry Clin Neurosci 59:504–507
   PubMed Web of Science ®Google Scholar
• Katoh M, Nakajima M, Shimada N, et al. (2000). Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: Prediction of in vivo drug–drug interactions. Eur J Clin Pharmacol 55:843–852
   PubMed Web of Science ®Google Scholar
• Kawanishi C, Furuno T, Kishida I, et al. (2002). A patient with treatment-resistant schizophrenia and cytochrome P4502D6 gene duplication. Clin Genet 61:152–154
   PubMed Web of Science ®Google Scholar
• Kawanishi C, Shimoda Y, Fujimaki J, et al. (1998). Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. J Neurol Sci 160:102–104
   PubMed Web of Science ®Google Scholar
• Kerry NL, Somogyi AA, Bochner F, Mikus G. (1994). The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: In vitro studies using human liver microsomes. Br J Clin Pharmacol 38:243–248
   PubMed Web of Science ®Google Scholar
• Ketter TA, Flockhart DA, Post RM, et al. (1995). The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 15:387–398
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Nickchen K, Bauer M, et al. (2004). Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442–473
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Schmidt H, Tzvetkov M, et al. (2007). Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 7:257–265
   PubMed Web of Science ®Google Scholar
• Kirchmair J, Mannhold R, Kubinyi H, Folkers G. (2014). Drug metabolism prediction. Weinheim: Wiley
   Google Scholar
• Kirkwood LC, Nation RL, Somogyi AA. (1997). Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. Br J Clin Pharmacol 44:549–555
   PubMed Web of Science ®Google Scholar
• Kitchen I, Tremblay J, Andre J, et al. (1979). Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica 9:397–404
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Ishizuka T, Shimada N, et al. (1999a). Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 27:763–766
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Nakajima M, Oshima K, et al. (1999b). Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos 27:860–865
   PubMed Web of Science ®Google Scholar
• Kosel S, Lucking CB, Egensperger R, et al. (1996). Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy-body parkinsonism. J Neurosci Res 44:174–183
   PubMed Web of Science ®Google Scholar
• Koudriakova T, Iatsimirskaia E, Utkin I, et al. (1998). Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26:552–561
   PubMed Web of Science ®Google Scholar
• Koyama E, Chiba K, Tani M, Ishizaki T. (1996). Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther 278:21–30
   PubMed Web of Science ®Google Scholar
• Koyama E, Chiba K, Tani M, Ishizaki T. (1997). Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: A study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 281:1199–1210
   PubMed Web of Science ®Google Scholar
• Kroemer HK, Eichelbaum M. (1995). “It's the genes, stupid”. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56:2285–2298
   Google Scholar
• Ku HY, Ahn HJ, Seo KA, et al. (2008). The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos 36:986–990
   PubMed Web of Science ®Google Scholar
• Kudo S, Odomi M. (1998). Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. Eur J Clin Pharmacol 54:253–259
   PubMed Web of Science ®Google Scholar
• Kutz K. (1993). Pharmacology, toxicology and human pharmacokinetics of tropisetron. Ann Oncol 4:15–18
   PubMed Web of Science ®Google Scholar
• Lang DH, Rettie AE. (2000). In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): Metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol 50:311–314
   PubMed Web of Science ®Google Scholar
• Lang DH, Rettie AE, Bocker RH. (1997). Identification of enzymes involved in the metabolism of atrazine, terbuthylazine, ametryne, and terbutryne in human liver microsomes. Chem Res Toxicol 10:1037–1044
   PubMed Web of Science ®Google Scholar
• Lemoine A, Gautier JC, Azoulay D, et al. (1993). Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 43:827–832
   PubMed Web of Science ®Google Scholar
• Lessard E, Fortin A, Belanger PM, et al. (1997). Role of CYP2D6 in the N-hydroxylation of procainamide. Pharmacogenetics 7:381–390
   PubMedGoogle Scholar
• Li X, Cameron MD. (2012). Potential role of a quetiapine metabolite in quetiapine-induced neutropenia and agranulocytosis. Chem Res Toxicol 25:1004–1011
   PubMed Web of Science ®Google Scholar
• Li XQ, Bjorkman A, Andersson TB, et al. (2002). Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: A new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 300:399–407
   PubMed Web of Science ®Google Scholar
• Lightfoot T, Ellis SW, Mahling J, et al. (2000). Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: Implications for active site modelling. Xenobiotica 30:219–233
   PubMed Web of Science ®Google Scholar
• Lin LY, Di Stefano EW, Schmitz DA, et al. (1997). Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos 25:1059–1064
   PubMed Web of Science ®Google Scholar
• Liu R, Liu J, Tawa G, Wallqvist A. (2012). 2D SMARTCyp reactivity-based site of metabolism prediction for major drug-metabolizing cytochrome P450 enzymes. J Chem Inf Model 52:1698–1712
   PubMed Web of Science ®Google Scholar
• Liu Y, Bilfinger TV, Stefano GB. (1997). A rapid and sensitive quantitation method of endogenous morphine in human plasma. Life Sci 60:237–243
   PubMed Web of Science ®Google Scholar
• Liu Z, Mortimer O, Smith CA, et al. (1995). Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism. Br J Clin Pharmacol 39:77–80
   PubMed Web of Science ®Google Scholar
• Llerena A, Berecz R, de la Rubia A, Dorado P. (2002). QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol 16:361–364
   PubMed Web of Science ®Google Scholar
• Llerena A, Cobaleda J, Benitez J. (1989). Debrisoquine hydroxylation phenotypes in healthy volunteers. Lancet 1:1398
   PubMed Web of Science ®Google Scholar
• Llerena A, Edman G, Cobaleda J, et al. (1993). Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 87:23–28
   PubMed Web of Science ®Google Scholar
• Loghin C, Haber H, Beasley CM Jr, et al. (2013). Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers. Br J Clin Pharmacol 75:538–549
   PubMed Web of Science ®Google Scholar
• Long JP, Fitzgerald O, Maurer BJ. (1980). Hepatotoxicity following treatment with perhexiline maleate. Ir Med J 73:275–276
   PubMedGoogle Scholar
• MacKerell AD Jr, Banavali N, Foloppe N. (2000). Development and current status of the CHARMM force field for nucleic acids. Biopolymers 56:257–265
   PubMed Web of Science ®Google Scholar
• Madani S, Paine MF, Lewis L, et al. (1999). Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res 16:1199–1205
   PubMed Web of Science ®Google Scholar
• Mann A, Miksys SL, Gaedigk A, et al. (2012). The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. Neurobiol Aging 33:2160–2171
   PubMed Web of Science ®Google Scholar
• Mannens GS, Snel CA, Hendrickx J, et al. (2002). The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos 30:553–563
   PubMed Web of Science ®Google Scholar
• Margolis JM, O'Donnell JP, Mankowski DC, et al. (2000). (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 28:1187–1191
   PubMed Web of Science ®Google Scholar
• McEnroe JD, Fleishaker JC. (2005). Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet 44:237–246
   PubMed Web of Science ®Google Scholar
• McQuinn RL, Quarfoth GJ, Johnson JD, et al. (1984). Biotransformation and elimination of 14C-flecainide acetate in humans. Drug Metab Dispos 12:414–420
   PubMed Web of Science ®Google Scholar
• Mellon RD, Bayer BM. (1998). Role of central opioid receptor subtypes in morphine-induced alterations in peripheral lymphocyte activity. Brain Res 789:56–67
   PubMed Web of Science ®Google Scholar
• Mellstrom B, von Bahr C. (1981). Demethylation and hydroxylation of amitriptyline, nortriptyline, and 10-hydroxyamitriptyline in human liver microsomes. Drug Metab Dispos 9:565–568
   PubMed Web of Science ®Google Scholar
• Michalets EL, Smith LK, Van Tassel ED. (1998). Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother 32:761–765
   PubMed Web of Science ®Google Scholar
• Miksys S, Tyndale RF. (2006). Nicotine induces brain CYP enzymes: Relevance to Parkinson's disease. J Neural Transm Suppl 70:177–180
   PubMed Web of Science ®Google Scholar
• Miller RT, Miksys S, Hoffmann E, Tyndale RF. (2014). Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys. Br J Pharmacol 171:3077–3088
   PubMed Web of Science ®Google Scholar
• Minder EI, Meier PJ, Muller HK, et al. (1984). Bufuralol metabolism in human liver: A sensitive probe for the debrisoquine-type polymorphism of drug oxidation. Eur J Clin Invest 14:184–189
   PubMed Web of Science ®Google Scholar
• Molden E, Asberg A, Christensen H. (2000). CYP2D6 is involved in O-demethylation of diltiazem. An in vitro study with transfected human liver cells. Eur J Clin Pharmacol 56:575–579
   PubMed Web of Science ®Google Scholar
• Molden E, Lunde H, Lunder N, Refsum H. (2006). Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 28:744–749
   PubMed Web of Science ®Google Scholar
• Mortimer O, Lindstrom B, Laurell H, et al. (1989). Dextromethorphan: Polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. Br J Clin Pharmacol 27:223–227
   PubMed Web of Science ®Google Scholar
• Mount DL, Patchen LC, Nguyen-Dinh P, et al. (1986). Sensitive analysis of blood for amodiaquine and three metabolites by high-performance liquid chromatography with electrochemical detection. J Chromatogr 383:375–386
   PubMed Web of Science ®Google Scholar
• Muralidharan G, Cooper JK, Hawes EM, et al. (1996). Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine. Eur J Clin Pharmacol 50:121–128
   PubMed Web of Science ®Google Scholar
• Murphy PJ. (1974). Metabolic pathways of aprindine. Acta Cardiol Suppl 18:131–142
   Google Scholar
• Muscatello MR, Bruno A, Pandolfo G, et al. (2010). Emerging treatments in the management of schizophrenia – focus on sertindole. Drug Des Devel Ther 4:187–201
   PubMed Web of Science ®Google Scholar
• Mutch E, Williams FM. (2006). Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology 224:22–32
   PubMed Web of Science ®Google Scholar
• Mutlib AE, Klein JT. (1998). Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther 286:1285–1293
   PubMed Web of Science ®Google Scholar
• Mutlib AE, Strupczewski JT, Chesson SM. (1995). Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone. Drug Metab Dispos 23:951–964
   PubMed Web of Science ®Google Scholar
• Myatt JW, Healy MP, Bravi GS, et al. (2010). Pyrazolopyridazine alpha-2-delta-1 ligands for the treatment of neuropathic pain. Bioorg Med Chem Lett 20:4683–4688
   PubMed Web of Science ®Google Scholar
• Nakajima M, Kobayashi K, Oshima K, et al. (1999a). Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. Xenobiotica 29:885–898
   PubMed Web of Science ®Google Scholar
• Nakajima M, Nakamura S, Tokudome S, et al. (1999b). Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: Evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 27:1381–1391
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yamamoto T, Nunoya K, et al. (1996). Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212–1217
   PubMed Web of Science ®Google Scholar
• Nakamura A, Hirota T, Morino A, et al. (1999). Cytochrome P450 isoforms responsible for the N-deethylation and cyclohexane-hydroxylation of NS-21. Xenobiotica 29:243–252
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yokoi T, Inoue K, et al. (1996). CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics 6:449–457
   PubMedGoogle Scholar
• Narimatsu S, Kato R, Horie T, et al. (1999). Enantioselectivity of bunitrolol 4-hydroxylation is reversed by the change of an amino acid residue from valine to methionine at position 374 of cytochrome P450-2D6. Chirality 11:1–9
   PubMed Web of Science ®Google Scholar
• Narimatsu S, Watanabe T, Masubuchi Y, et al. (1995). Characterization of a chemically reactive propranolol metabolite that binds to microsomal proteins of rat liver. Chem Res Toxicol 8:721–728
   PubMed Web of Science ®Google Scholar
• Nau R, Sorgel F, Eiffert H. (2010). Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 23:858–883
   PubMed Web of Science ®Google Scholar
• Nelson JC, Mazure CM, Jatlow PI. (1995). Desipramine treatment of major depression in patients over 75 years of age. J Clin Psychopharmacol 15:99–105
   PubMed Web of Science ®Google Scholar
• Niwa T, Okada K, Hiroi T, et al. (2008). Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain. Biol Pharm Bull 31:348–351
   PubMed Web of Science ®Google Scholar
• Niwa T, Sato R, Yabusaki Y, et al. (1999). Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica 29:187–193
   PubMed Web of Science ®Google Scholar
• Nordin C, Bertilsson L. (1995). Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline. Clin Pharmacokinet 28:26–40
   Google Scholar
• Oates NS, Shah RR, Idle JR, Smith RL. (1982). Genetic polymorphism of phenformin 4-hydroxylation. Clin Pharmacol Ther 32:81–89
   PubMed Web of Science ®Google Scholar
• Obach RS, Pablo J, Mash DC. (1998). Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metab Dispos 26:764–768
   PubMed Web of Science ®Google Scholar
• Ohyama K, Nakajima M, Nakamura S, et al. (2000). A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: An approach to predict the contribution with relative activity factor. Drug Metab Dispos 28:1303–1310
   PubMed Web of Science ®Google Scholar
• Olah J, Mulholland AJ, Harvey JN. (2011). Understanding the determinants of selectivity in drug metabolism through modeling of dextromethorphan oxidation by cytochrome P450. Proc Natl Acad Sci USA 108:6050–6055
   PubMed Web of Science ®Google Scholar
• Oldham HG, Clarke SE. (1997). In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(−)-carvedilol. Drug Metab Dispos 25:970–977
   PubMed Web of Science ®Google Scholar
• Olesen OV, Linnet K. (1999). Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 59:298–309
   PubMed Web of Science ®Google Scholar
• Olesen OV, Linnet K. (2000). Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol 50:563–571
   PubMed Web of Science ®Google Scholar
• Optibrium. (2014). StarDrop reference guide. Available from: http://www.optibrium.com/stardrop/stardrop-p450-models.php [last accessed Jul 2014]
   Google Scholar
• Otton SV, Schadel M, Cheung SW, et al. (1993). CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 54:463–472
   PubMed Web of Science ®Google Scholar
• Ozawa S, Ohta K, Miyajima A, et al. (2000). Metabolic activation of o-phenylphenol to a major cytotoxic metabolite, phenylhydroquinone: Role of human CYP1A2 and rat CYP2C11/CYP2E1. Xenobiotica 30:1005–1017
   PubMed Web of Science ®Google Scholar
• Paar WD, Poche S, Gerloff J, Dengler HJ. (1997). Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 53:235–239
   PubMed Web of Science ®Google Scholar
• Paine MJI, McLaughlin LA, Flanagan JU, et al. (2003). Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J Biol Chem 278:4021–4027
   PubMed Web of Science ®Google Scholar
• Patten CJ, Smith TJ, Murphy SE, et al. (1996). Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes. Arch Biochem Biophys 333:127–138
   PubMed Web of Science ®Google Scholar
• Peets EA, Jackson M, Symchowicz S. (1972). Metabolism of chlorpheniramine maleate in man. J Pharmacol Exp Ther 180:364–374
   PubMedGoogle Scholar
• Penas-Lledo EM, Dorado P, Aguera Z, et al. (2012). CYP2D6 polymorphism in patients with eating disorders. Pharmacogenomics J 12:173–175
   PubMed Web of Science ®Google Scholar
• Penas-Lledo EM, Trejo HD, Dorado P, et al. (2013). CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients. Mol Psychiatry 18:8–9
   PubMed Web of Science ®Google Scholar
• Pichard L, Gillet G, Bonfils C, et al. (1995). Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metab Dispos 23:1253–1262
   PubMed Web of Science ®Google Scholar
• Pinder RM, Van Delft AM. (1983). The potential therapeutic role of the enantiomers and metabolites of mianserin. Br J Clin Pharmacol 15:269s–276s
   Web of Science ®Google Scholar
• Pirmohamed M, Williams D, Madden S, et al. (1995). Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 272:984–990
   PubMed Web of Science ®Google Scholar
• Pivonka J, Segelman FH, Hartman CA, et al. (1987). Determination of azelastine and desmethylazelastine in human plasma by high-performance liquid chromatography. J Chromatogr 420:89–98
   PubMed Web of Science ®Google Scholar
• Poeaknapo C, Schmidt J, Brandsch M, et al. (2004). Endogenous formation of morphine in human cells. Proc Natl Acad Sci USA 101:14091–14096
   PubMed Web of Science ®Google Scholar
• Postlind H, Danielson A, Lindgren A, Andersson SH. (1998). Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 26:289–293
   PubMed Web of Science ®Google Scholar
• Prakash C, O'Donnell J, Khojasteh-Bakht SC. (2007). Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: Characterization of polar metabolites by chemical derivatization with dansyl chloride. Drug Metab Dispos 35:1071–1080
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Greenblatt DJ, Flockhart D, et al. (2007). Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 27:28–34
   PubMed Web of Science ®Google Scholar
• Prior TI, Chue PS, Tibbo P, Baker GB. (1999). Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 9:301–309
   PubMed Web of Science ®Google Scholar
• R: A language and environment for statistical computing. (2014). Available from: http://www.R-project.org/ [last accessed May 2015]
   Google Scholar
• Ray WA, Chung CP, Murray KT, et al. (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360:225–235
   PubMed Web of Science ®Google Scholar
• Ray WA, Meredith S, Thapa PB, et al. (2001). Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 58:1161–1167
   PubMed Web of Science ®Google Scholar
• Reed-Hagen AE, Tsuchiya M, Shimada K, et al. (1999). Pharmacokinetics of ezlopitant, a novel non-peptidic neurokinin-1 receptor antagonist in preclinical species and metabolite kinetics of the pharmacologically active metabolites. Biopharm Drug Dispos 20:429–439
   PubMed Web of Science ®Google Scholar
• Reith MK, Sproles GD, Cheng LK. (1995). Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist. Drug Metab Dispos 23:806–812
   PubMed Web of Science ®Google Scholar
• Rendic S. (2002). Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab Rev 34:83–448
   PubMed Web of Science ®Google Scholar
• Ring BJ, Catlow J, Lindsay TJ, et al. (1996). Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 276:658–666
   PubMed Web of Science ®Google Scholar
• Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. (2002). Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 30:319–323
   PubMed Web of Science ®Google Scholar
• Rodrigues AD, Kukulka MJ, Surber BW, et al. (1994). Measurement of liver microsomal cytochrome p450 (CYP2D6) activity using [O-methyl-14C]dextromethorphan. Anal Biochem 219:309–320
   PubMed Web of Science ®Google Scholar
• Roh HK, Chung JY, Oh DY, et al. (2001). Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 52:265–271
   PubMed Web of Science ®Google Scholar
• Roth BL, Choudhary MS, Khan N, Uluer AZ. (1997). High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2a receptors: Evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther 280:576–583
   PubMed Web of Science ®Google Scholar
• Rotzinger S, Fang J, Baker GB. (1998a). Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 26:572–575
   PubMed Web of Science ®Google Scholar
• Rotzinger S, Fang J, Coutts RT, Baker GB. (1998b). Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biol Psychiatry 44:1185–1191
   PubMed Web of Science ®Google Scholar
• Rowland P, Blaney FE, Smyth MG, et al. (2006). Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614–7622
   PubMed Web of Science ®Google Scholar
• Roy SD, Hawes EM, McKay G, et al. (1985). Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin. Clin Pharmacol Ther 38:128–133
   PubMed Web of Science ®Google Scholar
• Ruan J, Yang M, Fu P, et al. (2014). Metabolic activation of pyrrolizidine alkaloids: Insights into the structural and enzymatic basis. Chem Res Toxicol 27:1030–1039
   PubMed Web of Science ®Google Scholar
• Salva M, Jansat JM, Martinez-Tobed A, Palacios JM. (2003). Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos 31:404–411
   PubMed Web of Science ®Google Scholar
• Salva P, Costa J. (1995). Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet 29:142–153
   PubMed Web of Science ®Google Scholar
• Sams C, Mason HJ, Rawbone R. (2000). Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes. Toxicol Lett 116:217–221
   PubMed Web of Science ®Google Scholar
• Sanwald P, David M, Dow J. (1996). Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos 24:602–609
   PubMed Web of Science ®Google Scholar
• Satoh T, Fujita KI, Munakata H, et al. (2000). Studies on the interactions between drugs and estrogen: Analytical method for prediction system of gynecomastia induced by drugs on the inhibitory metabolism of estradiol using Escherichia coli coexpressing human CYP3A4 with human NADPH-cytochrome P450 reductase. Anal Biochem 286:179–186
   PubMed Web of Science ®Google Scholar
• Schadel M, Wu D, Otton SV, et al. (1995). Pharmacokinetics of dextromethorphan and metabolites in humans: Influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol 15:263–269
   PubMed Web of Science ®Google Scholar
• Scheer N, Kapelyukh Y, McEwan J, et al. (2012). Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. Mol Pharmacol 81:63–72
   PubMed Web of Science ®Google Scholar
• Schenk PW, van Fessem MAC, Verploegh-Van Rij S, et al. (2007). Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry 13:597–605
   PubMed Web of Science ®Google Scholar
• Schmider J, Greenblatt DJ, von Moltke LL, et al. (1996). Inhibition of cytochrome P450 by nefazodone in vitro: Studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 41:339–343
   PubMed Web of Science ®Google Scholar
• Schulz-Jander DA, Casida JE. (2002). Imidacloprid insecticide metabolism: Human cytochrome P450 isozymes differ in selectivity for imidazolidine oxidation versus nitroimine reduction. Toxicol Lett 132:65–70
   PubMed Web of Science ®Google Scholar
• Schuttelkopf AW, van Aalten DM. (2004). PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60:1355–1363
   PubMed Web of Science ®Google Scholar
• Shaffer JP. (1995). Multiple hypothesis testing. Annu Rev Psychol 561–576
   Web of Science ®Google Scholar
• Shah RR, Evans DA, Oates NS, et al. (1985). The genetic control of phenformin 4-hydroxylation. J Med Genet 22:361–366
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. (1996). Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab Dispos 24:515–522
   PubMed Web of Science ®Google Scholar
• Shimizu M, Takatori K, Kajiwara M, Ogata H. (1998). Isolation of a major metabolite (i-OHAP) of aprindine and its identification as N-[3-(N,N-diethylamino)propyl]-N-phenyl-2-aminoindan-5-ol. Biol Pharm Bull 21:530–534
   PubMed Web of Science ®Google Scholar
• Shin YG, Le H, Khojasteh C, Hop CE. (2011). Comparison of metabolic soft spot predictions of CYP3A4, CYP2C9 and CYP2D6 substrates using MetaSite and StarDrop. Comb Chem High Throughput Screen 14:811–823
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Guijarro P, Armada B, et al. (2014). Influence of combinations of drugs that act on the CYP2D6 metabolic pathway in the treatment of major depressive disorder: A population-based study. Eur Psychiatry 29:331–337
   PubMed Web of Science ®Google Scholar
• Siegle I, Fritz P, Eckhardt K, et al. (2001). Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11:237–245
   PubMedGoogle Scholar
• Singh M, Khanna VK, Shukla R, Parmar D. (2010). Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson's disease. Dis Markers 28:87–93
   PubMed Web of Science ®Google Scholar
• Skinner MH, Kuan HY, Pan A, et al. (2003). Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 73:170–177
   PubMed Web of Science ®Google Scholar
• Smith DA, Jones BC. (1992). Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 44:2089–2098
   PubMed Web of Science ®Google Scholar
• Smith TJ, Guo Z, Gonzalez FJ, et al. (1992). Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res 52:1757–1763
   PubMed Web of Science ®Google Scholar
• Snider NT, Sikora MJ, Sridar C, et al. (2008). The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp Ther 327:538–545
   PubMed Web of Science ®Google Scholar
• Soohoo DN, Van Natta K, Carlson TJ. (1999). Potent and selective mechanism-based inhibition of CYP2D6 by RO115-1954. ISSX Proceedings, 9th North American ISSX Meeting, Nashville, TN, USA, Vol. 15, 24–28 Oct; International Society for the Study of Xenobiotics, Cabin John, MD, 1999. p. 66–67
   Google Scholar
• Sorensen LB, Sorensen RN, Miners JO, et al. (2003). Polymorphic hydroxylation of perhexiline in vitro. Br J Clin Pharmacol 55:635–638
   PubMed Web of Science ®Google Scholar
• Stamer UM, Lee EH, Rauers NI, et al. (2011). CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care. Anesth Analg 113:48–54
   PubMed Web of Science ®Google Scholar
• Stefano GB. (1998). Autoimmunovascular regulation: Morphine and anandamide and ancondamide stimulated nitric oxide release. J Neuroimmunol 83:70–76
   PubMed Web of Science ®Google Scholar
• Stefano GB, Cadet P, Kream RM, Zhu W. (2008). The presence of endogenous morphine signaling in animals. Neurochem Res 33:1933–1939
   PubMed Web of Science ®Google Scholar
• Stefano GB, Scharrer B, Smith EM, et al. (1996). Opioid and opiate immunoregulatory processes. Crit Rev Immunol 16:109–144
   PubMed Web of Science ®Google Scholar
• Stiborova M, Poljakova J, Martinkova E, et al. (2012). Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5. Toxicology 302:233–241
   PubMed Web of Science ®Google Scholar
• Stingl JC, Viviani R. (2011). CYP2D6 in the brain: Impact on suicidality. Clin Pharmacol Ther 89:352–353
   PubMed Web of Science ®Google Scholar
• Stormer E, von Moltke LL, Shader RI, Greenblatt DJ. (2000). Metabolism of the antidepressant mirtazapine in vitro: Contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 28:1168–1175
   PubMed Web of Science ®Google Scholar
• Stresser DM, Kupfer D. (1997). Catalytic characteristics of CYP3A4: Requirement for a phenolic function in ortho hydroxylation of estradiol and mono-O-demethylated methoxychlor. Biochemistry 36:2203–2210
   PubMed Web of Science ®Google Scholar
• Stresser DM, Kupfer D. (1998). Prosubstrates of CYP3A4, the major human hepatic cytochrome P450: Transformation into substrates by other P450 isoforms. Biochem Pharmacol 55:1861–1871
   PubMed Web of Science ®Google Scholar
• Stringer RA, Strain-Damerell C, Nicklin P, Houston JB. (2009). Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab Dispos 37:1025–1034
   PubMed Web of Science ®Google Scholar
• Su Z, Martin R, Cox BF, Gintant G. (2004). Mesoridazine: An open-channel blocker of human ether-a-go-go-related gene K + channel. J Mol Cell Cardiol 36:151–160
   PubMed Web of Science ®Google Scholar
• Suzuki T, Fujita S, Narimatsu S, et al. (1992). Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes. FASEB J 6:771–776
   PubMed Web of Science ®Google Scholar
• Szabo C. (1995). Alterations in nitric oxide production in various forms of circulatory shock. New Horiz 3:2–32
   PubMedGoogle Scholar
• Tang J, Cao Y, Rose RL, Hodgson E. (2002). In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos. Chem Biol Interact 141:229–241
   PubMed Web of Science ®Google Scholar
• Tang L, Ye L, Lv C, et al. (2011). Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes. Toxicol Lett 202:47–54
   PubMed Web of Science ®Google Scholar
• Tateishi T, Watanabe M, Kumai T, et al. (2000). CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci 67:2913–2920
   PubMed Web of Science ®Google Scholar
• Tschen AC, Rieder MJ, Oyewumi LK, Freeman DJ. (1999). The cytotoxicity of clozapine metabolites: Implications for predicting clozapine-induced agranulocytosis. Clin Pharmacol Ther 65:526–532
   PubMed Web of Science ®Google Scholar
• Tsuneoka Y, Matsuo Y, Iwahashi K, et al. (1993). A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease. J Biochem 114:263–266
   PubMed Web of Science ®Google Scholar
• Tyndale RF, Li Y, Li NY, et al. (1999). Characterization of cytochrome P-450 2D1 activity in rat brain: High-affinity kinetics for dextromethorphan. Drug Metab Dispos 27:924–930
   PubMed Web of Science ®Google Scholar
• US FDA. (2009). Suicidal behavior and ideation and antiepileptic drugs. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100190.htm [last accessed May 2015]
   Google Scholar
• US FDA. (2013). FDA drug safety communication: Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/or adenoidectomy. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm339112.htm [last accessed Jul 2014]
   Google Scholar
• Usmani KA, Karoly ED, Hodgson E, Rose RL. (2004). In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily. Drug Metab Dispos 32:333–339
   PubMed Web of Science ®Google Scholar
• Usmani KA, Rose RL, Goldstein JA, et al. (2002). In vitro human metabolism and interactions of repellent N,N-diethyl-m-toluamide. Drug Metab Dispos 30:289–294
   PubMed Web of Science ®Google Scholar
• Uttamsingh V, Lu C, Miwa G, Gan L-S. (2005). Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos 33:1723–1728
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Greenblatt DJ, von Moltke LL, et al. (1998). Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: Dominance of CYP 2C19 and 3A4. J Clin Pharmacol 38:112–121
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Schmider J, Harmatz JS, et al. (2001). Relative contribution of CYP3A to amitriptyline clearance in humans: In vitro and in vivo studies. J Clin Pharmacol 41:1043–1054
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. (2000). Microsomal binding of amitriptyline: Effect on estimation of enzyme kinetic parameters in vitro. J Pharmacol Exp Ther 293:343–350
   PubMed Web of Science ®Google Scholar
• Vigneault P, Kaddar N, Bourgault S, et al. (2011). Prolongation of cardiac ventricular repolarization under paliperidone: How and how much? J Cardiovasc Pharmacol 57:690–695
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Duan SX, et al. (1998a). Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: Relation to drug interactions in vivo. J Pharm Sci 87:1184–1189
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Duan SX, et al. (1997). Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology (Berlin) 132:402–407
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Granda BW, et al. (1999a). Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 48:89–97
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Granda BW, et al. (1999b). Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: Cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berlin) 145:113–122
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Grassi JM, et al. (1998b). Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: Human cytochromes mediating transformation and cytochrome inhibitory effects. Psychopharmacology (Berlin) 140:293–299
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Grassi JM, et al. (1999c). Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry 46:839–849
   PubMed Web of Science ®Google Scholar
• Voorman RL, Maio SM, Hauer MJ, et al. (1998a). Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: Probable involvement of CYP2D6 and CYP3A. Drug Metab Dispos 26:631–639
   PubMed Web of Science ®Google Scholar
• Voorman RL, Maio SM, Payne NA, et al. (1998b). Microsomal metabolism of delavirdine: Evidence for mechanism-based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther 287:381–388
   PubMed Web of Science ®Google Scholar
• Voorman RL, Payne NA, Wienkers LC, et al. (2001). Interaction of delavirdine with human liver microsomal cytochrome P450: Inhibition of CYP2C9, CYP2C19, and CYP2D6. Drug Metab Dispos 29:41–47
   PubMed Web of Science ®Google Scholar
• Voronov P, Przybylo HJ, Jagannathan N. (2007). Apnea in a child after oral codeine: A genetic variant – an ultra-rapid metabolizer. Pediatr Anesth 17:684–687
   PubMed Web of Science ®Google Scholar
• Wang B, Yang LP, Zhang XZ, et al. (2009). New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev 41:573–643
   PubMed Web of Science ®Google Scholar
• Wang JS, Backman JT, Taavitsainen P, et al. (2000). Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 28:959–965
   PubMed Web of Science ®Google Scholar
• Wang JS, DeVane CL. (2003). Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 31:742–747
   PubMed Web of Science ®Google Scholar
• Ward SA, Walle T, Walle UK, et al. (1989). Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 45:72–79
   PubMed Web of Science ®Google Scholar
• Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ. (2000). In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions. Drug Metab Dispos 28:392–397
   PubMed Web of Science ®Google Scholar
• Wen B, Ma L, Rodrigues AD, Zhu M. (2008). Detection of novel reactive metabolites of trazodone: Evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos 36:841–850
   PubMed Web of Science ®Google Scholar
• Williams DG, Patel A, Howard RF. (2002). Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth 89:839–845
   PubMed Web of Science ®Google Scholar
• Wishart DS, Knox C, Guo AC, et al. (2008). DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36:D901–D906
   PubMed Web of Science ®Google Scholar
• Wojcikowski J, Maurel P, Daniel WA. (2006). Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab Dispos 34:471–476
   PubMed Web of Science ®Google Scholar
• Wojcikowski J, Pichard-Garcia L, Maurel P, Daniel WA. (2003). Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol 138:1465–1474
   PubMed Web of Science ®Google Scholar
• Woo SI, Hansen LA, Yu X, et al. (1999). Alternative splicing patterns of CYP2D genes in human brain and neurodegenerative disorders. Neurology 53:1570–1572
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inoue K, Hashimoto M, Shimada T. (1999). Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol 73:65–70
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Hidestrand M, Spina E, et al. (2001). Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 29:1263–1268
   PubMed Web of Science ®Google Scholar
• Yoshii K, Kobayashi K, Tsumuji M, et al. (2000). Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci 67:175–184
   PubMed Web of Science ®Google Scholar
• Yu A, Dong H, Lang D, Haining RL. (2001). Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metab Dispos 29:1362–1365
   PubMed Web of Science ®Google Scholar
• Yu A, Haining RL. (2001). Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: Can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos 29:1514–1520
   PubMed Web of Science ®Google Scholar
• Yu AM, Idle JR, Byrd LG, et al. (2003a). Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13:173–181
   PubMedGoogle Scholar
• Yu AM, Idle JR, Gonzalez FJ. (2004). Polymorphic cytochrome P450 2D6: Humanized mouse model and endogenous substrates. Drug Metab Rev 36:243–277
   PubMed Web of Science ®Google Scholar
• Yu AM, Idle JR, Herraiz T, et al. (2003b). Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13:307–319
   PubMedGoogle Scholar
• Yu AM, Idle JR, Krausz KW, et al. (2003c). Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 305:315–322
   PubMed Web of Science ®Google Scholar
• Yu J, Paine MJ, Marechal JD, et al. (2006). In silico prediction of drug binding to CYP2D6: Identification of a new metabolite of metoclopramide. Drug Metab Dispos 34:1386–1392
   PubMed Web of Science ®Google Scholar
• Yue J, Miksys S, Hoffmann E, Tyndale RF. (2008). Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: An investigation of induction and time course. J Psychiatry Neurosci 33:54–63
   PubMed Web of Science ®Google Scholar
• Yury K, Roland W. (2014). CYP2D6 substrates and drug metabolism. In: Baumann P, ed. CYP2D6: Genetics, pharmacology and clinical relevance. London: Future Medicine Ltd, 80–100
   Google Scholar
• Zackrisson AL, Lindblom B, Ahlner J. (2010). High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther 88:354–359
   PubMed Web of Science ®Google Scholar
• Zanger UM, Raimundo S, Eichelbaum M. (2004). Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23–37
   PubMed Web of Science ®Google Scholar
• Zaretzki J, Bergeron C, Huang TW, et al. (2013). RS-WebPredictor: A server for predicting CYP-mediated sites of metabolism on drug-like molecules. Bioinformatics 29:497–498
   PubMed Web of Science ®Google Scholar
• Zhang JO, Augustin B, Testino T, et al. (1999). In vitro biotransformation of fluvoxamine maleate: Identification of cytochrome P450 2D6 as the catalyzing isozyme in human hepatic microsomes. ISSX Proceedings of the 9th North American ISSX Meeting, Nashville, TN, USA, Vol. 15, 1999 Oct 24–28; International Society for the Study of Xenobiotics, Cabin John, MD, 108
   Google Scholar
• Zhou L, Erickson RR, Hardwick JP, et al. (1997). Catalysis of the cysteine conjugation and protein binding of acetaminophen by microsomes from a human lymphoblast line transfected with the cDNAs of various forms of human cytochrome P450. J Pharmacol Exp Ther 281:785–790
   PubMed Web of Science ®Google Scholar
• Zhou SF, Liu JP, Lai XS. (2009). Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem 16:2661–2805
   PubMed Web of Science ®Google Scholar
• Zhu W, Mantione KJ, Shen L, et al. (2005). Tyrosine and tyramine increase endogenous ganglionic morphine and dopamine levels in vitro and in vivo: CYP2D6 and tyrosine hydroxylase modulation demonstrates a dopamine coupling. Med Sci Monit 11:Br397–Br404
   PubMed Web of Science ®Google Scholar
• Zivkovic M, Mihaljevic-Peles A, Sagud M, et al. (2010). The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: Two case reports with three episodes. Psychiatr Danub 22:112–116
   PubMed Web of Science ®Google Scholar
• Zuber R, Anzenbacherova E, Anzenbacher P. (2002). Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6:189–198
   PubMed Web of Science ®Google Scholar